ASCO: FOLFOX Noninferior to Chemoradiotherapy for Overall Survival in Rectal Cancer

FRIDAY, June 9, 2023 -- Neoadjuvant chemotherapy with fluorouracil, leucovorin, and oxaliplatin (FOLFOX) is noninferior to preoperative chemoradiotherapy with respect to overall survival for patients with locally advanced rectal cancer who are...
Source: Drugs.com - Pharma News - Category: Pharmaceuticals Source Type: news